alemtuzumab (Campath)

a therapeutic antibody directed against the CDw52 antigen expressed by the lymphocytes and has proven lytic abilities both in vitro & in vivo; has been sequenced; do not confuse with Campath-1H antigen

Also Known As:

Networked: 983 relevant articles (148 outcomes, 176 trials/studies)

Relationship Network

Drug Context: Research Results

Experts

1.	Coles, Alasdair J: 21 articles (12/2014 - 01/2006)
2.	Mackinnon, Stephen: 19 articles (01/2015 - 02/2002)
3.	Hale, Geoff: 17 articles (03/2015 - 02/2002)
4.	Osterborg, Anders: 14 articles (11/2011 - 01/2002)
5.	Keating, Michael J: 14 articles (08/2011 - 05/2002)
6.	Pagliuca, Antonio: 13 articles (03/2015 - 09/2002)
7.	Mufti, Ghulam J: 13 articles (07/2014 - 09/2002)
8.	Hallek, Michael: 13 articles (08/2013 - 01/2002)
9.	Faderl, Stefan: 13 articles (06/2013 - 08/2003)
10.	O'Brien, Susan: 13 articles (08/2011 - 01/2004)

Related Diseases

1.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 03/01/2012 - "Alemtuzumab has been shown to be effective in poor-prognosis chronic lymphocytic leukemia (CLL); treatment, however, has been associated with significant toxicity. " 06/01/2007 - "With respect to outcomes such as survival, response rate, response duration, time to progression, and quality of life, is alemtuzumab a beneficial treatment option for patients with B-cell chronic lymphocytic leukemia (cll)?What toxicities are associated with the use of alemtuzumab?Which" 06/01/2009 - "Alemtuzumab in chronic lymphocytic leukemia treatment: retrospective analysis of outcome according to cytogenetics Alemtuzumab is effective in B-cell chronic lymphocytic leukemia (CLL) with 17p deletion, which responds poorly to chemotherapeutic agents. " 01/15/2005 - "The anti-CD52 antibody alemtuzumab is effective in the treatment of patients with chronic lymphocytic leukemia (CLL). " 03/15/2004 - "Alemtuzumab therapy is effective for some refractory chronic lymphocytic leukemia (CLL), but identifying responders requires at least 8 weeks of therapy. "
2.	Relapsing-Remitting Multiple Sclerosis 07/01/2009 - "Phase II clinical trials revealed that the lymphocyte-depleting humanized monoclonal antibody alemtuzumab (Campath-1H) is highly effective in the treatment of early relapsing-remitting multiple sclerosis. " 01/01/2010 - "Treatment with alemtuzumab is highly effective in relapsing-remitting multiple sclerosis; however, 30% of patients develop autoimmunity. " 11/24/2012 - "For patients with first-line treatment-refractory relapsing-remitting multiple sclerosis, alemtuzumab could be used to reduce relapse rates and sustained accumulation of disability. " 01/01/2015 - "Alemtuzumab, a humanized monoclonal antibody against CD52, is effective in the treatment of early relapsing-remitting multiple sclerosis (MS). " 03/01/2014 - "Alemtuzumab is an effective treatment for patients with relapsing-remitting multiple sclerosis, and has a generally acceptable tolerability profile. "
3.	Graft vs Host Disease (Graft-Versus-Host Disease) 07/01/2012 - "Factors predicting OS (P value by log rank <0·05) were: comorbidity index <3, FISH rank (Dohner) and 17p deletion, alemtuzumab pre-HSCT, achievement of CR post-HSCT, donor chimerism >90%, clearance of FISH abnormality post-HSCT and absence of high-grade (3-4) graft-versus-host disease. " 01/01/2014 - "The incidence of de novo chronic graft-versus-host disease (GVHD) was low at 19%, illustrating the efficacy of alemtuzumab for GVHD prophylaxis. " 05/01/2013 - "Phase I study of alemtuzumab for therapy of steroid-refractory chronic graft-versus-host disease." 05/01/2009 - "Alemtuzumab as treatment of steroid-refractory acute graft-versus-host disease: results of a phase II study." 10/01/2015 - "The incidence of severe acute graft-versus-host disease tended to be higher after the lower alemtuzumab dose (17% versus 4%; P = .15). "
4.	Multiple Sclerosis 08/01/2012 - "Alemtuzumab is an anti-CD52 monoclonal antibody with remarkable efficacy in relapsing multiple sclerosis (MS). " 01/01/2015 - "In clinical trials, alemtuzumab has shown impressive efficacy with regard to clinical and radiological outcomes in relapsing multiple sclerosis, along with sustained long-term beneficial effects, and it is attractive for its once-yearly administration. " 10/23/2008 - "Alemtuzumab, a humanized monoclonal antibody that targets CD52 on lymphocytes and monocytes, may be an effective treatment for early multiple sclerosis. " 01/01/2015 - "Comparative efficacy of alemtuzumab and established treatment in the management of multiple sclerosis." 04/01/2009 - "[Possibilities and risks of the monoclonal antibody alemtuzumab as a new treatment option for multiple sclerosis]."
5.	Infection 02/01/2006 - "Alemtuzumab (Campath-1H)-based conditioning regimens are effective in preventing GVHD, but are associated with very high rates of cytomegalovirus (CMV) infection, a major limitation to their use. " 08/01/2005 - "Low-dose alemtuzumab induced significant responses in these patients (16% complete remission, 25% partial remission), with mild hematologic and extrahematologic side effects and a low rate of infections, even in the presence of long-lasting severe immunosuppression." 11/01/2007 - "We report a case of Sézary syndrome treated successfully with alemtuzumab but who died of treatment-related infection." 04/01/2003 - "Thus elimination of late mortalities related to chronic GVHD and a rapid immune reconstitution, limiting either infection or relapse related deaths, contributed to an improved outcome following T-cell depletion with Campath-1H "in the bag"." 10/10/2010 - "Alemtuzumab consolidation improved CR and MRD-negative rates after FR induction but caused serious infections in patients who had already achieved CR after induction and did not improve 2-year PFS or survival."

Related Drugs and Biologics

1.	fludarabine
2.	rituximab (Mabthera)
3.	alemtuzumab (Campath)
4.	Interferons
5.	Monoclonal Antibodies
6.	Cyclophosphamide (Cytoxan)
7.	interferon beta 1a
8.	natalizumab (Tysabri)
9.	daclizumab (dacliximab)
10.	ofatumumab

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Stem Cell Transplantation
3.	Transplants (Transplant)
4.	Transplantation (Transplant Recipients)
5.	Hematopoietic Stem Cell Transplantation